Recent news

2022-05-22

Karma CREME results: Topical endoxifen lowered breast density, but came with unacceptable skin toxicity. 

In the 3-armed double-blinded randomized clinical trial Karma CREME we found that a daily local application on the breast skin with a lotion, containing the tamoxifen metabolite Z-endoxifen, can lower the mammographic breast density already after a few weeks of use. Ninety women, 30 in each dose arm, were randomized to placebo, 10 and 20...

---

2021-11-01

CYP2D6 genotype predicts tamoxifen discontinuation and drug response in the KARISMA trial

In an analysis of the KARISMA trial investigating tamoxifen response by CYP2D6 metabolizer status we found that discontinuation was higher in poor CYP2D6 metabolizers compared to less efficient metabolizers. One in three ultrarapid CYP2D6 metabolizers discontinued tamoxifen therapy within 1 month, which is substantially higher than in poor metabolizers. In addition we demonstrated that poor CYP2D6 metabolizers...

---

2021-03-19

KARISMA results: Low dose of tamoxifen have a potential treatment effect

The results from the 6-armed RCT trial KARISMA 2 show that 2.5 mg of tamoxifen has the potential to be as effective in reducing incidence and recurrence of breast cancer as the established 20 mg dose.  Mammographic density change is a proxy for tamoxifen therapy response. We tested if lower doses of tamoxifen were non-inferior...

---